Stocks · Healthcare · Drug Manufacturers - General
Bristol-Myers Squibb Company BMY
$61.15 -0.50% Close, Oct 2, 2026 · NYSE · Market cap $124.91B
High qualityInexpensive vs sectorLow risk
Next earnings report: Oct 29, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $4.54, up 83.4% year over year.
- Earnings beat analyst estimates in each of the last 12 quarters (average surprise over the last four: +12.1%).
- The shares trade at 13.5× trailing earnings, lower than 87% of the company's own readings over the past five years.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth43Weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 35%
- EPS growth (TTM, YoY)Top 16%
- FCF growth (TTM, YoY)Bottom 25%
- Revenue growth, 3-year CAGRBottom 27%
- Revenue growth accelerationTop 33%
Quality84Strong
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 8%
- Gross marginTop 42%
- Operating marginTop 8%
- Cash conversion (OCF / net income)Bottom 40%
- Accruals (lower is better)Bottom 34%
- Net debt / EBITDA (lower is better)Bottom 38%
- Interest coverTop 18%
Value93Exceptional
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 5%
- Free-cash-flow yieldTop 8%
- EBITDA / enterprise valueTop 9%
- Sales / enterprise valueTop 42%
- P/E vs own 5-year history (lower is better)Top 27%
Momentum66Positive
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 37%
- 6-month returnBottom 45%
- 1-year return vs S&P 500Top 37%
- Distance from 52-week highTop 17%
- Trend checklist (0–4)Top 39%
Revisions50Neutral
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 34%
- Consecutive EPS beatsTop 4%
- Share of analysts rating BuyBottom 14%
- Upside to consensus price targetBottom 22%
Stability95Exceptional
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 5%
- Maximum drawdown, 3 yearsTop 6%
- Beta vs S&P 500 (lower is better)Top 6%
- Net debt / EBITDA (lower is better)Bottom 38%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 1.8% | 3.1% | ↑ |
| EPS growth (YoY) | 33.6% | 83.4% | ↑ |
| Gross margin | 65.2% | 70.2% | ↑ |
| Operating margin | 25.3% | 28.3% | ↑ |
| FCF margin | 30.6% | 23.3% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 3.1% | 1.8% | ↑ | Bottom 35% |
| EPS growth (TTM, YoY) | 83.4% | 33.6% | ↑ | Top 16% |
| Gross margin | 70.2% | 65.2% | ↑ | Top 42% |
| Operating margin | 28.3% | 25.3% | ↑ | Top 8% |
| Net margin | 18.9% | 10.6% | ↑ | — |
| Free-cash-flow margin | 23.3% | 30.6% | ↓ | — |
| Return on invested capital | 15.5% | — | Top 8% | |
| Revenue growth, 3-year CAGR | 1.4% | — | Bottom 27% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.38×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.0%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.1%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -33.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 2.06×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 8.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 4.08%
- Net buyback yield (TTM)
- 0.10%
- Shareholder yield
- 4.18%
- Share count change, 1 year
- +0.5%
- Share count change, 3-year CAGR
- -0.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 12
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +12.1%
- Average 2-day reaction, last 8
- +1.9%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $69.22
- Target vs current price
- +13.2%
- Analysts with a rating
- 42
- Share rating Buy or Strong Buy
- 48%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | +27.5% | +2.8% | +0.8% | +7.1% | — |
| Apr 30, 2026 | +11.3% | +5.2% | -1.8% | -1.2% | +8.6% |
| Feb 5, 2026 | +2.4% | +3.3% | +4.0% | +5.4% | +1.0% |
| Oct 30, 2025 | +7.2% | +7.1% | +9.1% | +15.6% | +30.4% |
| Jul 31, 2025 | +33.9% | -5.8% | -2.5% | +3.6% | -4.7% |
| Apr 24, 2025 | +20.8% | +0.4% | +3.5% | -3.1% | -3.8% |
| Feb 6, 2025 | +13.6% | -3.8% | -6.0% | +0.8% | -15.3% |
| Oct 31, 2024 | +20.8% | +5.9% | +5.0% | +12.6% | +12.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | $2.04 | $1.60 | +27.5% | $12.97B |
| Apr 30, 2026 | $1.58 | $1.42 | +11.3% | $11.49B |
| Feb 5, 2026 | $1.26 | $1.23 | +2.4% | $12.50B |
| Oct 30, 2025 | $1.63 | $1.52 | +7.2% | $12.22B |
| Jul 31, 2025 | $1.46 | $1.09 | +33.9% | $12.27B |
| Apr 24, 2025 | $1.80 | $1.49 | +20.8% | $11.20B |
| Feb 6, 2025 | $1.67 | $1.47 | +13.6% | $12.34B |
| Oct 31, 2024 | $1.80 | $1.49 | +20.8% | $11.89B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 13.5× | 17.5× | 13th | Top 5% |
| P/E (forward) | 8.8× | — | — | — |
| EV / EBITDA | 9.6× | — | — | Top 9% |
| EV / Sales | 3.24× | — | — | Top 42% |
| Free-cash-flow yield | 9.16% | — | — | Top 8% |
| Earnings yield | 7.42% | — | — | Top 5% |
P/E over the past five years
Range 12.6× – 26.7× since Dec 31, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +28.9%
- Earnings per share growth (TTM)
- +83.4%
- Change in P/E multiple
- -18.3%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 209
- 50-day average slope (20 days)
- +2.9%
- 200-day average slope (20 days)
- +2.3%
- Distance from 50-day average
- -5.2%
- Distance from 200-day average
- +3.0%
- RSI (14)
- 37.9
- Relative volume
- 0.84×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 25.3%
- Volatility vs own 5-year history
- 56th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.22
- Correlation with S&P 500
- 0.13
- Current drawdown from 1-year high
- -10.2%
- Maximum drawdown, 3 years
- -32.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 2, 2022 | Jul 5, 2024 | -51.1% | 397 days | Not yet recovered |
| Aug 3, 2021 | Nov 30, 2021 | -22.6% | 83 days | 65 days (Mar 4, 2022) |
| Jun 27, 2022 | Aug 29, 2022 | -16.5% | 44 days | 50 days (Nov 8, 2022) |
| Jan 19, 2021 | Mar 4, 2021 | -11.1% | 31 days | 54 days (May 20, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $124.91B
- P/E (TTM)
- 13.5
- EPS, diluted (TTM)
- $4.54
- Revenue (TTM)
- $49.19B
- Dividend yield
- 4.12%
- 52-week range
- $42.52 – $68.64
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $46.38B | $46.16B | $45.01B | $48.30B | $48.20B |
| Gross profit | $26.76B | $26.49B | $25.36B | $27.43B | $34.26B |
| Operating income | $9.54B | $9.27B | $8.47B | $9.66B | $13.72B |
| Net income | $6.99B | $6.33B | $8.03B | -$8.95B | $7.05B |
| EPS (diluted) | $3.12 | $2.95 | $3.86 | -$4.41 | $3.45 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B | $12.97B |
| Net income | $1.21B | $72.0M | $2.46B | $1.31B | $2.20B | $1.09B | $2.68B | $3.32B |
| EPS (diluted) | $0.60 | $0.04 | $1.20 | $0.64 | $1.08 | $0.53 | $1.31 | $1.62 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $16.21B | $13.07B | $13.86B | $15.19B | $14.16B |
| Capital expenditure | -$973.0M | -$1.12B | -$1.21B | -$1.25B | -$1.31B |
| Free cash flow | $15.23B | $11.95B | $12.65B | $13.94B | $12.85B |
| Dividends paid | -$4.40B | -$4.63B | -$4.74B | -$4.86B | -$5.04B |
| Net share buybacks | -$6.29B | -$8.00B | -$5.16B | -$106.0M | -$128.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $11.07B
- Total assets
- $87.63B
- Total liabilities
- $65.31B
- Total debt
- $43.12B
- Net debt
- $34.40B
- Shareholders’ equity
- $22.32B
As of Jun 30, 2026 (filed Jul 30, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Oct 2, 2026 | $0.63 | Nov 2, 2026 |
| Jul 2, 2026 | $0.63 | Aug 3, 2026 |
| Apr 2, 2026 | $0.63 | May 1, 2026 |
| Jan 2, 2026 | $0.63 | Feb 2, 2026 |
| Oct 3, 2025 | $0.62 | Nov 3, 2025 |
| Jul 3, 2025 | $0.62 | Aug 1, 2025 |
| Apr 4, 2025 | $0.62 | May 1, 2025 |
| Jan 3, 2025 | $0.62 | Feb 3, 2025 |
Short interest
- Shares sold short
- 41,969,577
- Days to cover
- 5.80
- Change vs previous report
- -4.8%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Aug 7, 2001
- 1,000,000-for-951,777
- Mar 1, 1999
- 2-for-1
- Mar 3, 1997
- 2-for-1
- Jun 10, 1987
- 2-for-1
- May 27, 1983
- 2-for-1